Navigation Links
SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma
Date:9/10/2007

l trial for CS and the only intranasal antifungal that has been submitted to the FDA as an Investigative New Drug (IND). The initial study population is with patients that have severe CS who have undergone sinus surgery, but who are struggling with recurrent CS.

Despite the fact that there are over 60 million patients in the U.S. and EU that have CS, and that CS is by far the most common chronic respiratory disease with a commercial market approximately twice the size of asthma, there is currently no approved prescription pharmaceutical available for treatment of the disease. If approved, SinuNase will be the first therapy available to treat sufferers of CS.

Accentia Biopharmaceuticals is commercializing SinuTest for the confirmation of CS. Investigators at Mayo discovered that a ubiquitous, normally innocuous mold, Alternaria, colonizes in the mucus of the nose and sinus of virtually everybody. However, it was found that in patients with CS, this non-invasive mold elicits an eosinophilic inflammatory response characterized by the release of eMBP in the mucus, which then damages the mucosal epithelial lining of the nose and sinuses, leading to the inflammatory mucosal changes characteristic of CS. The SinuTest diagnostic uses a small sample of mucus from the patient's nose and tests for eMBP, which is uniquely detectable in the nasal mucin of patients with CS.


'/>"/>

Contact: Adam Holdsworth
aholdsworth@investorrelationsgroup.com
212-825-3210
The Investor Relations Group
Source:Eurekalert

Page: 1 2

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Worlds largest rainforest drying experiment completes first phase
3. Kinovate Life Sciences Launches Nittophase?High Performance Solid Support For Oligonucleatide Synthesis
4. Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses
5. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
6. Ebola DNA vaccine produces immune responses in all fully vaccinated volunteers in Phase 1 trial
7. NIH announces phase III clinical trial of creatine for Parkinsons disease
8. Farm kids almost twice as likely to die from injury as children overall
9. Chronic pain up almost 40 percent among US workers in past decade
10. Hunger in America rises by 43 percent over last five years
11. Method slashes quantum dot costs by 80 percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... YORK , Dec. 8, 2014 You,ve been ... banking account but can,t remember your password, site key or ... Who was your first grade teacher? Today, ... the app that will finally put an end ... – 1U TM . 1U leverages a user,s ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... plant geneticists and crop scientists has pioneered an economical ... boost levels of provitamin A, the precursors that are ... help to enhance the nutritional status of millions of ... is described this week in the journal Science. ...
... Genetic Alliance, an organization devoted to accelerating the translation ... healthcare, has named Genetic Testing as its official journal. Genetic ... Inc. ... Genetic Testing, says Sharon Terry, President and CEO of Genetic ...
... Australias extinct marsupial lion (Thylacoleo carnifex) would have made ... the two big hyper-carnivores ever squared off in a ... New research published in the Journal of Zoology ... type teeth to scissor through hide and flesh to ...
Cached Biology News:Team finds an economical way to boost the vitamin A content of maize 2Team finds an economical way to boost the vitamin A content of maize 3Genetic Alliance names Genetic Testing as its official journal 2Marsupial lion tops African lion in fight to death 2
(Date:12/17/2014)... Xeno Diagnostics has again received an ... COLA inspection. Xeno has met all criteria for ... organization. Accreditation is earned only by laboratories that ... demonstrate continued accuracy in the performance of proficiency ... , While the Laboratory Excellence award ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
(Date:12/17/2014)... Dec. 17, 2014  United Therapeutics Corporation (NASDAQ: ... as well as changes to Martine Rothblatt , ... United Therapeutics announced the promotion of ... Executive Officer and David Zaccardelli , Pharm.D. to ... with these promotions, Dr. Rothblatt,s title will change from ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... everything from explosives to tainted milk, materials for use ... by a University of Houston (UH) chemist and his ... "There are many dangerous substances, pollutants and ... Advincula, a highly cited materials scientist at UH. "Our ...
... February 7, 2011 -- A low cost, nanometer-sized drug ... burns, has been developed by a group of scientists from ... in the U.S. and Japan. Diabetes is a ... the world,s population. Poor blood circulation arising from diabetes often ...
... Feb. 16, 2011 / PRNewswire/ -- Sigma-Aldrich® ... following executive leadership appointments intended to more closely ... Frank Wicks, President Research, will assume ... including those in Research Essentials, Research Specialties and ...
Cached Biology Technology:Sensors to detect explosives, monitor food being developed at UH 2Sensors to detect explosives, monitor food being developed at UH 3Sigma-Aldrich Announces Organizational Changes 2Sigma-Aldrich Announces Organizational Changes 3
... multi-purpose, high gel-strength agarose suitable for a ... conventional constant field to Pulsed Field Gel ... strength and exclusion limits, Multi ABgarose can ... running times. This in turn means reduced ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Rabbit polyclonal to L Kynurenine ( Abpromise for all tested applications). Antigen: Synthetic peptide L Kynurenine conjugated to a protein carrier. Entrez Gene ID: 8942 Swiss Protein ID...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
Biology Products: